Phase 2 (n = 20) | |
---|---|
Female gender, n (%) | 14 (70) |
Age in years, mean (SD) median | 44.3 (9) 44.6 |
Age at onset in years, mean (SD) median | 33.4 (10) 35.5 |
Disease duration in years, mean (SD) median | 10.9 (7.1) 10 |
Disease course, n (%) | |
RR | 13 (65) |
RP | 7 (35) |
EDSS, mean (SD) median | 3.9 (1.5) 3.8 |
Type of treatment, n (%) | |
Interferon beta | 15 (75) |
Glatiramer acetate | 4 (20) |
Combination | 0 (0) |
Others | 1 (5) |
VH CCSVI criterion, n (%) | |
VH1 | 8 (40) |
VH2 | 19 (95) |
VH3 | 20 (100) |
VH4 | 14 (70) |
VH5 | 4 (20) |
≥2 CCSVI criteria*, n (%) | 20 (100) |
≥2 CCSVI extracranial criteria, n (%) | 20 (100) |